Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats.
Liu Z, Geng W, Jiang C, Zhao S, Liu Y, Zhang Y, Qin S, Li C, Zhang X, Si Y · Experimental biology and medicine (Maywood, N.J.) · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats.” is organized in H2HUBB under the research focus hydrogen-rich saline inflammation immune study 2017 liu. The publication is cited as Liu Z, Geng W, Jiang C, Zhao S, Liu Y, Zhang Y, Qin S, Li C, Zhang X, Si Y, Experimental biology and medicine (Maywood, N.J.), 2017. This animal study examined Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats. The abstract describes Rat model; hydrogen delivered as hydrogen-rich saline and injected or infused hydrogen; reported duration 12 weeks. The abstract reports: ELISA assay showed hydrogen-rich saline lowered the levels of pro-inflammatory cytokines (IL-8 and IL-6) and anti-inflammatory cytokine IL-10 in bronchoalveolar lavage fluid and serum…. This is an automated editorial draft based on the abstract and requires source review before publication.
Hydrogen-rich saline inflammation immune study 2017 liu overview
The purpose of this study is to evaluate the protective effect of hydrogen-rich saline, a novel antioxidant, on chronic obstructive pulmonary disease and explore… Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.
Study design and hydrogen intervention
Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Rat model. Blinding: Unknown. Control status: Unknown.
Delivery method: Hydrogen-rich saline. Treatment duration: 12 weeks.
Reported findings and scientific interpretation
For this hydrogen-rich saline inflammation immune study 2017 liu, the study record reports the following: The abstract reports: ELISA assay showed hydrogen-rich saline lowered the levels of pro-inflammatory cytokines (IL-8 and IL-6) and anti-inflammatory cytokine IL-10 in bronchoalveolar lavage fluid and serum…
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Preclinical animal findings may not translate directly to human outcomes.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.